CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that data from its preclinical pipeline will be presented during the American Association for Cancer Research (AACR) Annual Meeting, to be held April 18-25 in Philadelphia, Pa. The presentations include findings on four new epigenetic targets: CARM1, PRMT6, SMYD3 and SETDB1. The Company will also present new pre-clinical data on DOT1L.
Help employers find you! Check out all the jobs and post your resume.
